Gemcitabine Versus Reduced-dose Combination Chemotherapy in Fragile Patients with Non-resectable Pancreatic Cancer

The aim of the study is to compare the efficacy and toxicity of full-dose Gemcitabine and reduced-dose combination chemotherapy in patients with non-resectable pancreatic cancer, who are unfit for full-dose combination chemotherapy. The patients will be equally randomized to arm A or arm B: Arm A: Full-dose single agent treatment with Gemcitabine 1000 mg/m2 weekly on days 1, 8,and 15 every 4 weeks. Arm B: Reduced-dose (80%) combination-treatment with Gemcitabine plus Nab-Paclitaxel (Gemcitabine: 800 mg/m2 plus Nab-Paclitaxel: 100 mg/m2 on day 1, 8 and 15 every 4 weeks) Progression-free sur

Trial Details

NCT ID

NCT05841420

Phase

PHASE2

Sponsor

Morten Ladekarl

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

• Gemcitabine
• Nab paclitaxel

Locations (sample)

• Aalborg, Denmark|57.048,9.9187

Key Eligibility Criteria

• Age ≥ 18 years
• Adenocarcinoma of the pancreas, histopathologically or cytologically verified
• Non-resectable (locally advanced or metastatic) PC
• Patients unfit or not candidate for full-dose combination chemotherapy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →